Amgen has been pulled up by the US Food and Drug Administration over promotion for its Neulasta Onpro on-body injector version of pegfilgrastim, which the agency said “makes false or misleading claims and representations about the benefit of Neulasta when administered through the Onpro on-body injector compared to a pre-filled syringe.”
Neulasta currently holds around two-thirds of the US pegfilgrastim market despite biosimilar competition, with the bulk of this coming from...






